Ionis Pharmaceuticals (IONS) Consolidated Net Income (2009 - 2026)

Ionis Pharmaceuticals' Consolidated Net Income history runs 18 years deep, the most recent figure standing at -$92.5 million for Q1 2026.

• In Q1 2026, Consolidated Net Income rose 37.03% year-over-year to -$92.5 million; the TTM figure through Mar 2026 stood at -$328.6 million (up 28.37% YoY), while the FY2025 annual figure was -$383.0 million, up 15.75% from the prior year.
• Consolidated Net Income was -$92.5 million for Q1 2026 at Ionis Pharmaceuticals, up from -$231.0 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $123.6 million in Q2 2025 to a low of -$231.0 million in Q4 2025.
• Historically, Consolidated Net Income has averaged -$92.2 million across 5 years, with a median of -$105.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Consolidated Net Income slumped 1033.67% in 2024, then jumped 286.45% in 2025.
• A 5-year view of Consolidated Net Income shows it stood at -$53.0 million in 2022, then jumped by 82.51% to -$9.3 million in 2023, then plunged by 1033.67% to -$105.0 million in 2024, then slumped by 119.95% to -$231.0 million in 2025, then jumped by 59.94% to -$92.5 million in 2026.
• The last three Consolidated Net Income figures came in at -$92.5 million (Q1 2026), -$231.0 million (Q4 2025), and -$128.6 million (Q3 2025), per Business Quant data.